Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Go back to Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
CANADIAN SUPERIOR ENERGY, Inc. (NYSE: SNG) Delayed: 0.67 --0 (-0%)
Previous Close $0.67    52 Week High $1.15 
Open $32.59    52 Week Low $0.46 
Day High $0.67    P/E N/A 
Day Low $0.67    EPS $0.00 
Volume 786,028